COX-1抑制剂II是靶向Cox催化位点（环加氧酶）的可透过细胞的苯磺酰胺化合物。COX-1抑制剂II抑制Cox-1（IC | 50 |为3.2μM）的选择性要高于Cox-2（IC | 50 |大于100μM）。与阿司匹林相似，COX-1抑制剂II具有相似的体内止痛活性，但与阿司匹林和消炎痛不同，COX-1抑制剂II不会引起胃功能紊乱。揭示该化合物除了抑制Cox-2表达外，还抑制PCA反应，并通过抑制ERK的磷酸化发挥抗炎作用。 COX-1 Inhibitor II is a cell-permeable benzenesulfonamide compound that targets the catalytic site of Cox (cyclooxygenase). COX-1 Inhibitor II inhibits Cox-1 (IC|50|of 3.2 μM) more selectively than Cox-2 (IC|50|of > 100 μM). Much like Aspirin , COX-1 Inhibitor II has shown similar|in vivo|analgesic activity, yet unlike Aspirin and Indomethacin, COX-1 Inhibitor II does not induce gastric disturbance. The compound was revealed to inhibit PCA response in addition to Cox-2 expression and to exert anti-inflammatory effects by suppressing phosphorylation of ERK.